Valuation : Immunic, Inc.

Market Cap 199M 172M 162M 147M 275M 18.79B 277M 1.91B 743M 9.61B 747M 731M 31.56B P/E 2026 *
-4.05x
P/E 2027 * -5.98x
Enterprise Value -80.96M -69.85M -65.8M -59.95M -112M -7.65B -113M -779M -302M -3.91B -304M -297M -12.85B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.03%
Yield 2026 *
-
Yield 2027 * -
1 day-2.33%
1 week-13.64%
Current month-9.87%
1 month+0.99%
3 months-2.73%
6 months+34.34%
Current year+166.82%
1 week 14.1
Extreme 14.1
16.7
1 month 13.68
Extreme 13.68
17.43
Current year 5.37
Extreme 5.372
17.43
1 year 5.06
Extreme 5.062
17.43
3 years 5.06
Extreme 5.062
21.1
5 years 5.06
Extreme 5.062
145
10 years 5.06
Extreme 5.062
289.9
Manager TitleAgeSince
Chief Executive Officer 48 01/06/2026
President 49 12/07/2024
Director of Finance/CFO 58 17/04/2020
Director TitleAgeSince
Director/Board Member 59 01/04/2019
Chairman 55 01/01/2019
Director/Board Member 64 19/11/2019
Date Insider Type Main position Quantity % Market Cap. Importance
06/08/26 Free

Director

50,740 0.3725%
05/07/26 Free

Director

25,370 0.1862%
05/07/26 Free

Director

25,370 0.1862%
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-13.64%+78.22%-13.17% 199M
+1.03%-3.11%+39.80%+94.60% 68.21B
+1.62%+2.43%+48.66%+88.33% 64.25B
+4.21%+1.80%-12.85%+380.20% 26.54B
+1.83%-7.77%+3.17%-14.91% 25.61B
+1.30%-0.96%+32.58%-17.99% 19.88B
-0.38%-12.42%+224.86%+373.18% 17.13B
+0.65%-5.83%+1.44%+544.44% 14.93B
+2.88%+4.33%+57.42%+162.82% 14.1B
+1.53%+1.49%+25.41%+196.44% 12.45B
Average +1.23%-4.50%+49.87%+179.40% 26.33B
Weighted average by Cap. +1.60%-3.02%+42.71%+154.72%

Financials

2026 *2027 *
Net sales - -
Net income -138M -119M -112M -102M -191M -13.06B -193M -1.33B -516M -6.68B -519M -508M -21.93B -152M -131M -123M -112M -210M -14.33B -212M -1.46B -566M -7.33B -570M -557M -24.07B
Net Debt -280M -241M -227M -207M -387M -26.44B -390M -2.69B -1.05B -13.52B -1.05B -1.03B -44.41B -404M -348M -328M -299M -559M -38.15B -563M -3.89B -1.51B -19.5B -1.52B -1.48B -64.06B
Logo Immunic, Inc.
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Employees
100
Date Price Change Volume
03/09/26 $14.24 -2.33% 225,011
01/09/26 $14.58 -7.72% 230,232
31/08/26 $15.80 +2.60% 124,872
28/08/26 $15.40 -5.52% 357,934
27/08/26 $16.30 -1.15% 162,880
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
14.58USD
Average target price
43.09USD
Spread / Average Target
+195.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMUX Stock